Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies
Background: Monoclonal antibodies (mAbs) have demonstrated substantial potential in the treatment of intraocular diseases. This review aimed to comprehensively evaluate the applications, efficacy, and safety of mAbs in the management of intraocular conditions. Methods: A comprehensive literature sea...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/13/4/86 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850240388060676096 |
|---|---|
| author | Yuan Zong Miki Miyagaki Mingming Yang Jing Zhang Yaru Zou Kyoko Ohno-Matsui Koju Kamoi |
| author_facet | Yuan Zong Miki Miyagaki Mingming Yang Jing Zhang Yaru Zou Kyoko Ohno-Matsui Koju Kamoi |
| author_sort | Yuan Zong |
| collection | DOAJ |
| description | Background: Monoclonal antibodies (mAbs) have demonstrated substantial potential in the treatment of intraocular diseases. This review aimed to comprehensively evaluate the applications, efficacy, and safety of mAbs in the management of intraocular conditions. Methods: A comprehensive literature search was conducted in major medical databases through July 2024. Relevant studies on monoclonal antibodies for intraocular diseases were included. Two independent researchers screened the literature, extracted data, and assessed study quality. Cost-effectiveness analyses were also reviewed. Results: Anti-vascular endothelial growth factor (VEGF) antibodies, such as bevacizumab, ranibizumab, and aflibercept, showed significant therapeutic effects in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Tumor necrosis factor-alpha (TNF-α) inhibitors demonstrated promising results in treating noninfectious uveitis. Complement system-targeted therapies like pegcetacoplan offered new options for geographic atrophy. Anti-VEGF antibodies showed potential in managing retinopathy of prematurity (ROP). However, challenges persist, including high costs, potential drug resistance, and limited long-term safety data in certain scenarios. Conclusions: Monoclonal antibodies are vital for treating intraocular diseases, but continuous innovation and rigorous clinical evaluation are essential. Future research should focus on developing novel delivery systems, exploring combination therapies, conducting long-term follow-up studies, and investigating personalized treatment strategies to provide safer, more effective, and cost-effective therapeutic solutions. |
| format | Article |
| id | doaj-art-79c3ad0fedbc405189f860def3e1735d |
| institution | OA Journals |
| issn | 2073-4468 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj-art-79c3ad0fedbc405189f860def3e1735d2025-08-20T02:00:52ZengMDPI AGAntibodies2073-44682024-10-011348610.3390/antib13040086Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging TherapiesYuan Zong0Miki Miyagaki1Mingming Yang2Jing Zhang3Yaru Zou4Kyoko Ohno-Matsui5Koju Kamoi6Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanDepartment of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanDepartment of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanDepartment of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanDepartment of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanDepartment of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanDepartment of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8510, JapanBackground: Monoclonal antibodies (mAbs) have demonstrated substantial potential in the treatment of intraocular diseases. This review aimed to comprehensively evaluate the applications, efficacy, and safety of mAbs in the management of intraocular conditions. Methods: A comprehensive literature search was conducted in major medical databases through July 2024. Relevant studies on monoclonal antibodies for intraocular diseases were included. Two independent researchers screened the literature, extracted data, and assessed study quality. Cost-effectiveness analyses were also reviewed. Results: Anti-vascular endothelial growth factor (VEGF) antibodies, such as bevacizumab, ranibizumab, and aflibercept, showed significant therapeutic effects in neovascular age-related macular degeneration (NVAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Tumor necrosis factor-alpha (TNF-α) inhibitors demonstrated promising results in treating noninfectious uveitis. Complement system-targeted therapies like pegcetacoplan offered new options for geographic atrophy. Anti-VEGF antibodies showed potential in managing retinopathy of prematurity (ROP). However, challenges persist, including high costs, potential drug resistance, and limited long-term safety data in certain scenarios. Conclusions: Monoclonal antibodies are vital for treating intraocular diseases, but continuous innovation and rigorous clinical evaluation are essential. Future research should focus on developing novel delivery systems, exploring combination therapies, conducting long-term follow-up studies, and investigating personalized treatment strategies to provide safer, more effective, and cost-effective therapeutic solutions.https://www.mdpi.com/2073-4468/13/4/86monoclonal antibodies (mAbs)anti-VEGF therapyintraocular diseasesnon-infectious uveitisage-related macular degeneration (AMD)retinal vein occlusion (RVO) |
| spellingShingle | Yuan Zong Miki Miyagaki Mingming Yang Jing Zhang Yaru Zou Kyoko Ohno-Matsui Koju Kamoi Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies Antibodies monoclonal antibodies (mAbs) anti-VEGF therapy intraocular diseases non-infectious uveitis age-related macular degeneration (AMD) retinal vein occlusion (RVO) |
| title | Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies |
| title_full | Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies |
| title_fullStr | Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies |
| title_full_unstemmed | Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies |
| title_short | Ophthalmic Use of Targeted Biologics in the Management of Intraocular Diseases: Current and Emerging Therapies |
| title_sort | ophthalmic use of targeted biologics in the management of intraocular diseases current and emerging therapies |
| topic | monoclonal antibodies (mAbs) anti-VEGF therapy intraocular diseases non-infectious uveitis age-related macular degeneration (AMD) retinal vein occlusion (RVO) |
| url | https://www.mdpi.com/2073-4468/13/4/86 |
| work_keys_str_mv | AT yuanzong ophthalmicuseoftargetedbiologicsinthemanagementofintraoculardiseasescurrentandemergingtherapies AT mikimiyagaki ophthalmicuseoftargetedbiologicsinthemanagementofintraoculardiseasescurrentandemergingtherapies AT mingmingyang ophthalmicuseoftargetedbiologicsinthemanagementofintraoculardiseasescurrentandemergingtherapies AT jingzhang ophthalmicuseoftargetedbiologicsinthemanagementofintraoculardiseasescurrentandemergingtherapies AT yaruzou ophthalmicuseoftargetedbiologicsinthemanagementofintraoculardiseasescurrentandemergingtherapies AT kyokoohnomatsui ophthalmicuseoftargetedbiologicsinthemanagementofintraoculardiseasescurrentandemergingtherapies AT kojukamoi ophthalmicuseoftargetedbiologicsinthemanagementofintraoculardiseasescurrentandemergingtherapies |